BRP, identified through peptide prediction, may revolutionize weight loss treatment, offering efficacy without the ...

BRP emerges as a promising peptide for weight loss, activating appetite control pathways without triggering nausea, paving ...

The identification of BRP, an anti-obesity peptide, showcases the transformative role of AI in drug discovery and its ...

Investigating GLP-1 RAs reveals their impact on women's health, addressing metabolic disorders, reproductive health, and ...

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

GLP-1 drugs, originally for type 2 diabetes, are increasingly used for weight loss, but they can worsen eating disorders. Rapid weight loss from these drugs can reinforce harmful eating behaviors ...

Vivani also expects the results to support the potential application of a GLP-1 (exenatide) implant for type 2 diabetes and other diseases. Find out which stock just plummeted to the bottom of the ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has been shown to help people struggling with alcohol use disorder (AUD) reduce the amount they drink – pointing to yet another potential use ...

Novo Nordisk has filed another Citizen's Petition with the FDA seeking to block compounding pharmacies in the US from making versions of one of its GLP-1 agonist drugs. The latest attempt focuses ...

For the last 2 years, compounded versions of glucagon-like peptide 1 (GLP-1) medications have been big business. Nearly 137 million American adults are eligible to use these costly drugs to treat ...

This story mentions weight, weight loss, and/or GLP-1 drugs. In the last few years, GLP-1s, prescription weight-loss medications for adults with obesity or with overweight and at least one weight ...